Theravance Biopharma to Report Q1 2024 Earnings on May 13

Theravance Biopharma is set to release its Q1 2024 earnings on May 13, with analysts predicting a loss of $0.253 per share on revenue of $14.0 million. The company will hold an earnings conference call to discuss its financial results and pipeline progress.

author-image
Aqsa Younas Rana
New Update
Theravance Biopharma to Report Q1 2024 Earnings on May 13

Theravance Biopharma to Report Q1 2024 Earnings on May 13

Theravance Biopharma (TBPH) is set to release its first quarter 2024 earnings results on Monday, May 13. Analysts are predicting a loss of $0.253 per share on revenue of $14.0 million, which would represent a 33.97% increase over the prior year quarter.

Why this matters: The earnings report of Theravance Biopharma, a biopharmaceutical company focused on organ-selective medicines, has significant implications for the medical industry and investors. A strong revenue growth could indicate a promising future for the company's pipeline of programs targeting unmet patient needs, which could lead to breakthroughs in inflammation and immunology treatments.

Theravance Biopharma is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. The company's research is concentrated on inflammation and immunology, with a pipeline of internally discovered programs targeting significant unmet patient needs.

Theravance Biopharma's stock is currently trading at $9.38, down 16.5% from the beginning of the year. However, analysts see a possible upside of 118.6% from the current price, with an average 12-month price target of $20.50. The stock has a consensus rating of Buy, with 2 analysts rating it a Buy.

The company will hold an earnings conference call on Monday, May 13 at 5:00 PM Eastern Time to discuss the first quarter 2024 financial results. Interested parties can register for or listen to the call via the Investor Relations section of Theravance Biopharma's website.

Institutional investors hold a significant stake in Theravance Biopharma, with the top holders being Vanguard Group Inc, SG Americas Securities LLC, and Swiss National Bank. Insiders own 6.90% of the company's stock, while institutions hold 99.10% in total.

Analysts appear more bullish on Theravance Biopharma compared to other companies in the Medical sector. The stock's consensus Buy rating and average rating score of 3.00 are higher than the Moderate Buy average for the broader Medical industry. The company does not currently pay a dividend and has no long track record of dividend growth.

Theravance Biopharma's upcoming earnings report and subsequent conference call will provide important updates on the company's financial performance and pipeline progress. With analysts predicting strong revenue growth and a potential for significant stock upside, the company's results will be closely watched by investors and industry observers.

Key Takeaways

  • Theravance Biopharma (TBPH) to release Q1 2024 earnings on May 13.
  • Analysts predict loss of $0.253 per share on revenue of $14.0 million.
  • Strong revenue growth could indicate promising future for pipeline programs.
  • Analysts see 118.6% upside from current price, with average 12-month target of $20.50.
  • Earnings conference call on May 13 at 5:00 PM Eastern Time.